Bayer Sheds R&D Projects Ahead Of Joint Venture, Is Flexible On Control

Bayer is reducing the size of its R&D pipeline through product eliminations and outlicensing opportunities to maximize its influence over a future pharmaceutical partnership, Management Board Chairman Werner Wenning announced Nov. 12